Next-generation sequencing (NGS) is an efficient and sensitive method to detect mutations from ctDNA. Many features and clinical conditions could significantly affect the concordance between ctDNA and corresponding tumor tissues. Our goal was to systematically investigate the critical factors contributing to different concordance between ctDNA and corresponding tumor tissues. We recruited two groups of IIIB or IV lung cancer patients: The standard group to evaluate the accuracy of our method and the concordance between ctDNA and tumor tissues, and the study group with various clinical conditions. We applied our unique identification (UID) indexed capturing-based sequencing (UC-Seq) to ctDNA samples, and confirm the results by Droplet digital PCR (ddPCR). Considering mutations detected from NGS of tumor tissues as golden standard, UC-Seq achieved overall 93.6% sensitivity for SNVs and Indels, and 0.8 Pearson correlation between tumor TMB and bTMB. Efficacious treatments, long sampling date (more than 2 weeks) between tumor tissues and ctDNA and low concentrations of cfDNA (less than 9 ng/ml) could significantly decrease the concordance between ctDNA and tumor tissues. About 84% mutations showed shorter mutant fragment length than that of wild-type fragments, and the AFs of mutations could be significantly enriched in small-size ctDNA. In late-stage lung cancer patients, ctDNA generally has high concordance with tumor tissues. However it could be significantly affected by three clinical conditions which could dynamically change the content of ctDNA. Moreover, the detection limit could be further extended by enriching small-size ctDNA in the preparation of samples.
Lung adenocarcinoma (LADC) is a prevalent type of lung cancer that is associated with lung and gut microbiota. However, the interactions between these microbiota and cancer development remain unclear. In this study, a microbiome study was performed on paired fecal and bronchoalveolar lavage fluid (BALF) samples from 42 patients with LADC and 64 healthy controls using 16S rRNA gene amplicon and shotgun metagenome sequencing, aiming to correlate the lung and gut microbiota with LADC. Patients with LADC had reduced α-diversity in the gut microbiome and altered β-diversity compared with healthy controls, and the abundances of Flavonifractor, Eggerthella, and Clostridium were higher in the gut microbiome of LADC patients. The increased abundance of microbial species, such as Flavonifractor plautii, was associated with advanced-stage LADC and a higher metastasis rate. Phylogenetically, Haemophilus parainfluenzae was the most frequently shared taxon in the lung and gut microbiota of LADC patients. Gut microbiome functional pathways involving leucine, propanoate, and fatty acids were associated with LADC progression. In conclusion, the low diversity of the gut microbiota and the presence of H. parainfluenzae in gut and lung microbiota were linked to LADC development, while an increased abundance of F. plautii and the enriched metabolic pathways could be associated with the progression of LADC.
13 February 2023 in Journal of Cancer Research and Clinical Oncology
Recent advances in mass spectrometry and proteomics have revealed numerous novel lysine acylation modifications, which increase proteome functional diversity via covalent modification of lysine residues. Protein malonylation and succinylation are highly enriched in mitochondrial proteins. They use malonyl-CoA and succinyl-CoA which were primarily synthesized in mitochondria, as acyl donors and can modulate protein structure and function. However, conventional mass spectrometry-based workflows often suffer from limited coverage and may fail to detect low-abundance modification sites. Therefore, we present an organelle-centered proteomic protocol. By purifying mitochondria before enriching modified peptides, the protocol minimizes interference from non-mitochondrial proteins, thereby offering a valuable reference for investigating diverse protein acylation events in metabolic-associated fatty liver disease (MASLD) and other physiological and pathological contexts.
Background: Hepatocellular carcinoma (HCC), one of the leading contributors to the global cancer burden, often places patients in a dual predicament of pronounced death anxiety and suboptimal treatment adherence. Prior research has largely treated death anxiety and adherence as independent, homogeneous constructs, thereby overlooking potential within-population heterogeneity and their co-occurring patterns. This study adopted a person-centered approach to identify joint latent profiles of death anxiety and treatment adherence among patients with HCC and to examine factors associated with profile membership. Methods: A cross-sectional design was employed. From October to November 2025, 586 patients with HCC were recruited via convenience sampling from five tertiary general hospitals in Shenzhen, Beijing and Lhasa, China. Data were collected using the Death Anxiety Scale (DAS), General Medication Adherence Scale (GMAS), Health Literacy Scale Short-Form (HLS-SF), and Fear of Progression Questionnaire–Short Form (FoP-Q-SF). Results: Latent profile analysis identified three qualitatively distinct subgroups: low death anxiety–high treatment adherence, moderate death anxiety–moderate treatment adherence, and high death anxiety–low treatment adherence. Across profiles, death anxiety and treatment adherence exhibited a clear inverse co-variation pattern. Multinomial logistic regression indicated that health literacy and fear of disease progression were key psychosocial factors differentiating profile membership. In addition, demographic and disease-related variables showed varying predictive effects on profile assignment. Conclusions: Patients in the high death anxiety–low treatment adherence profile may represent a clinically important high-risk subgroup for targeted screening and supportive care. Clinical practice should emphasize assessment of health literacy and profile-specific psychosocial needs when planning stratified interventions. However, because of the cross-sectional design, the observed associations should not be interpreted causally, and longitudinal studies are needed to examine temporal transitions between profiles and their effects on subsequent treatment outcomes.